Project Details
Description
ABSTRACT: Toxoplasma gondii remains an important cause of neurologic infection in people living
with HIV/AIDS (PLWHA) and continues to cause high morbidity and mortality in PLWHA. The
predilection of this protozoan for the central nervous system causing necrotizing encephalitis
underlies its major presentation in PLWHA. Since it can be transmitted by food or water T. gondii is
also classified as a category B NIH priority pathogen. The ability of this opportunistic pathogen to
cause latent infection in the central nervous system with subsequent reactivation encephalitis, due to
the cell mediated immune defects seen in HIV infection, represents its major risk to PLWHA. The
estimated incidence of Toxoplasma encephalitis in the combination antiretroviral therapy (cART) era
is ∼4000 cases per year in the United States. T. gondii remains a common infection in patients with
persistent immune suppression (i.e., CD4 count under 100) and a presenting opportunistic infection in
patients not on cART. Following initial infection T. gondii disseminates as its rapidly proliferating
tachyzoite stage which then differentiates into the slowly replicating bradyzoite stage that is found in
tissue cysts in the central nervous system. These tissue cysts usually persist for the life of the host;
however, reactivation of this latent infection in PLWHA results in encephalitis. Tissue cysts, and the
cyst wall, are essential for the development of latent infection, survival of T. gondii during latency, and
reactivation of this opportunistic pathogen in PLWHA leading to Toxoplasma encephalitis. Several
lines of evidence suggest that bradyzoite differentiation is stress mediated and that the cyst wall (a
modified parasitophorous vacuole membrane) is made up of many stage specific proteins and
glycoproteins. Understanding the formation and composition of the cyst wall will inform strategies
(e.g., vaccine development and therapeutic agents) to eliminate latency and prevent AIDS associated
Toxoplasma encephalitis. We have developed techniques to characterize this structure and have
found several T. gondii cyst wall proteins that have been shown to prevent latent infection when used
as vaccine antigens. We have also identified CST1, which is a critical component of the cyst wall and
plays a role in the assembly of this structure. We now propose an integrated approach employing
state of the art proteomic, immunologic, and genetic techniques to characterize this critically important
structure. An improved understanding of the formation of the cyst wall will provide the basic
underpinnings of new strategies to eliminate latent infection thereby preventing AIDS associated
Toxoplasma encephalitis.
| Status | Active |
|---|---|
| Effective start/end date | 9/1/25 → 8/31/29 |
Funding
- National Institute of Allergy and Infectious Diseases: $2,456,732.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.